Table 2.

Risk of vulvar and vaginal cancer associated with HPV-16, 18, 33 antibodies: case-control studies of type-specific HPV seropositivity and pre-cancer and cancer.

Site and lesion	Serology						Reference code (see Table 5)
	HPV-16		HPV-18		HPV-33
	OR	95% CI	OR	95% CI	OR	95% CI
	VULVA
	Preneoplastic vulvar lesions	4.5	(3.1 – 6.4)	3.0	(0.9 – 10.2)	-		-	[Table 5: b1]
VIN3/Vulvar in situ	3.6	(2.6 – 4.8)	0.9	(0.6 – 1.5)	-	-	[Table 5: b2]
	13.4	(3.9 – 46.5)	-	-	-	-	[Table 5: b3]
VIN not other specified	5.4	(1.7 – 18.0)	-	-	-	-	[Table 5: b4]
Invasive vulvar cancer	2.9	(0.9 – 8.7)	-	-	-	-	[Table 5: b3]
	2.8	(1.7 – 4.7)	1.2	(0.5 – 2.7)	-	-	[Table 5: b2]
	3.7	(1.5 – 9.1)	-	-	-	-	[Table 5: b1]
Warty-basaloid	3.8	(0.8 – 18.9)	-	-	-	-	[Table 5: b3]
	4.5	(1.2 – 16.0)	-	-	-	-	[Table 5: b4]
Keratinising squamous	1.6	(0.4 – 7.4)	-	-	-	-	[Table 5: b3]
	1.3	(0.3 – 4.9)	-	-	-	-	[Table 5: b4]
Vulvar neoplasia (both pre and invasive)	4.4	(3.1 – 6.2)	3.8	(1.2 – 11.7)	-	-	[Table 5: b1]
	4.5	(3.0 – 6.8)	-	-	-	-	[Table 5: b2]
	5.3	(2.5 – 11.1)	-	-	-	-	[Table 5: b3]
VAGINA
Preneoplastic vaginal lesions	13.1	(5.6–30.4)	-	-	-	-	[Table 5: b1]
	4.2	(2.8–6.4)	2.1	(1.3 – 3.2)	-	-	[Table 5: b5]
Invasive vaginal cancer	6.3	(1.6–25.6)	-	-	-	-	[Table 5: b1]
	4.3	(2.8–8.7)	1.6	(0.7 – 3.6)	-	-	[Table 5: b5]
Vaginal neoplasia (both pre- and invasive)	10.9	(5.3–22.4)	-	-	-	-	[Table 5: b1]
	4.3	(3.0–6.2)	2	(1.3 – 2.9)	-	-	[Table 5: b5]
VULVA AND VAGINA
Preneoplastic vulvar and vaginal lesions	7.8	(1.4 – 80.0)	12.0	(1.2 – 590.0)	4.5	(0.5 – 54.0)	[Table 5: b6]
Invasive vulvar and vaginal cancer	5.5	(1.5 – 25.0)	1.5	(0.3 – 7.5)	3.3	(0.5 – 23.0)	[Table 5: b6]

CI: Confidence interval; OR: Odds ratio; VIN: Vulvar intraepithelial neoplasia.

Sources of data: [Table 5: b1–b6].